X4 Pharmaceuticals, Inc. (XFOR)Healthcare | Biotechnology | Boston, United States | NasdaqCM
4.05 USD
-0.36
(-8.163%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 4.05 |
Hot Take ↕ | July 11, 2026, 6:17 a.m. EDT
The long-term outlook is catastrophic. The company has suffered a 99.78% collapse over the last seven years, with the most recent annual return being a staggering -93.10%. This is not a temporary setback; it is a structural implosion where revenue has evaporated (-90.6% growth) and the business is burning cash aggressively. Despite a fortress-like balance sheet with minimal debt relative to its tiny size, the lack of revenue generation and negative returns on equity indicate a failed business model. The massive gap between the current price and the analyst mean target is a classic 'value trap' in biotech, reflecting the market's recognition that the pipeline has not yet delivered commercial viability. There is no margin of safety here, only the risk of total capital loss. In the short term, the stock is technically oversold and showing signs of a speculative bounce. The price has recovered slightly from its yearly lows, and options flow shows buyers stepping in for December expirations, hoping for a catalyst. However, this is a momentum play on a dying asset, not a turnaround story. The statistical forecast model offers no directional guidance, confirming the noise in the price action. Investors buying now are essentially gambling on a miracle cure that hasn't materialized in years. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.040079 |
| AutoETS | 0.040541 |
| MSTL | 0.054257 |
| AutoTheta | 0.079790 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 0.46 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.841 |
| Excess Kurtosis | 0.38 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 45.861 |
| Revenue per Share | 0.125 |
| Market Cap | 381,994,784 |
| Forward P/E | -4.94 |
| Beta | 0.35 |
| Website | https://www.x4pharma.com |
As of July 11, 2026, 6:17 a.m. EDT: Speculators are positioning for a modest rebound rather than a crash. Call volume is concentrated in December expirations at strikes above the current price, suggesting a speculative bet on recovery. Conversely, put activity is focused on near-term expirations at lower strikes, indicating a hedge against immediate volatility but not a deep bearish conviction on the long-term downside.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.9797297 |
| Address1 | 61 North Beacon Street |
| Address2 | 4th Floor |
| All Time High | 5,164.92 |
| All Time Low | 1.35 |
| Ask | 5.17 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,656,240 |
| Average Daily Volume3 Month | 610,578 |
| Average Volume | 610,578 |
| Average Volume10Days | 1,656,240 |
| Beta | 0.354 |
| Bid | 3.17 |
| Bid Size | 2 |
| Book Value | 1.786 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.05 |
| Current Ratio | 10.18 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.48 |
| Day Low | 4.015 |
| Debt To Equity | 45.861 |
| Display Name | X4 Pharmaceuticals |
| Dividend Date | 1,552,521,600 |
| Earnings Call Timestamp End | 1,746,102,600 |
| Earnings Call Timestamp Start | 1,746,102,600 |
| Earnings Timestamp | 1,778,070,600 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -89,685,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.515 |
| Enterprise To Revenue | 25.02 |
| Enterprise Value | 225,527,776 |
| Eps Current Year | -0.73 |
| Eps Forward | -0.82 |
| Eps Trailing Twelve Months | -2.07 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.0737 |
| Fifty Day Average Change | -0.02369976 |
| Fifty Day Average Change Percent | -0.005817748 |
| Fifty Two Week Change Percent | 197.97296 |
| Fifty Two Week High | 4.83 |
| Fifty Two Week High Change | -0.77999973 |
| Fifty Two Week High Change Percent | -0.16149063 |
| Fifty Two Week Low | 1.35 |
| Fifty Two Week Low Change | 2.7000003 |
| Fifty Two Week Low Change Percent | 2.0000002 |
| Fifty Two Week Range | 1.35 - 4.83 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,510,842,600,000 |
| Float Shares | 57,527,469 |
| Forward Eps | -0.82 |
| Forward P E | -4.9390244 |
| Free Cashflow | -55,171,752 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 45 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.81817 |
| Gross Profits | 7,375,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0053899996 |
| Held Percent Institutions | 0.99767 |
| Implied Shares Outstanding | 94,319,696 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,745,798,400 |
| Last Split Factor | 1:30 |
| Long Business Summary | X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts. |
| Long Name | X4 Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 381,994,784 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_283397098 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -99,722,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 415,478,260 |
| Number Of Analyst Opinions | 5 |
| Open | 4.41 |
| Operating Cashflow | -92,849,000 |
| Operating Margins | -7.4848604 |
| Payout Ratio | 0.0 |
| Phone | 857 529 8300 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 4.05 |
| Post Market Time | 1,783,973,405 |
| Previous Close | 4.41 |
| Price Eps Current Year | -5.5479455 |
| Price Hint | 4 |
| Price To Book | 2.2676373 |
| Price To Sales Trailing12 Months | 42.377945 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.879 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.36 |
| Regular Market Change Percent | -8.16326 |
| Regular Market Day High | 4.48 |
| Regular Market Day Low | 4.015 |
| Regular Market Day Range | 4.015 - 4.48 |
| Regular Market Open | 4.41 |
| Regular Market Previous Close | 4.41 |
| Regular Market Price | 4.05 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 641,739 |
| Return On Assets | -0.28326 |
| Return On Equity | -1.04206 |
| Revenue Growth | -0.906 |
| Revenue Per Share | 0.125 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 94,319,696 |
| Shares Percent Shares Out | 0.0584 |
| Shares Short | 5,507,057 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,371,418 |
| Short Name | X4 Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0585 |
| Short Ratio | 5.54 |
| Source Interval | 15 |
| State | MA |
| Symbol | XFOR |
| Target High Price | 13.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 11.6 |
| Target Median Price | 12.0 |
| Total Cash | 233,720,000 |
| Total Cash Per Share | 2.478 |
| Total Debt | 77,253,000 |
| Total Revenue | 9,014,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.07 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.822625 |
| Two Hundred Day Average Change | 0.22737527 |
| Two Hundred Day Average Change Percent | 0.05948145 |
| Type Disp | Equity |
| Volume | 641,739 |
| Website | https://www.x4pharma.com |
| Zip | 2,134 |